Background/Aims: Glioma is the most devastating cancer in the brain and has a poor prognosis in adults. Therefore, there is a critical need for novel therapeutic strategies for the management of glioma patients. Isogambogenic acid, an active compound extracted from the Chinese herb Garcinia hanburyi, induces autophagic cell death. Methods: Cell viability was detected with MTT assays. Cell proliferation was assessed using the colony formation assay. Morphological changes associated with autophagy and apoptosis were tested by TEM and Hoechst staining, respectively. The apoptosis rate was measured by flow cytometry. Western blot, immunofluorescence and immunohistochemical analyses were used to detect protein expression. U87-derived xenografts were established for the examination of the effect of isogambogenic acid on glioma growth in vivo. Results: Isogambogenic acid induced autophagic death in U87 and U251 cells, and blocking late-stage autophagy markedly enhanced the antiproliferative activities of isogambogenic acid. Moreover, we observed the activation of AMPK-mTOR signalling in isogambogenic acid-treated glioma cells. Furthermore, the activation of AMPK or the inhibition of mTOR augmented isogambogenic acid-induced autophagy. Inhibition of autophagy attenuated apoptosis in isogambogenic acid-treated glioma cells. Finally, isogambogenic acid inhibited the growth of U87 glioma in vivo. Conclusion: Isogambogenic acid inhibits the growth of glioma via activation of the AMPK-mTOR signalling pathway, which may provide evidence for future clinical applications in glioma therapy.
Measurement of cell viability
Human U87 and U251 glioma cell viabilities were detected by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; Sigma, M5655) method. Cells were seeded in 96-well culture plates and treated. Then, 20 μl of MTT (5 mg/ml) was added to each well. After a 4 h incubation, the supernatant was aspirated and 150 μl of DMSO was added to each well. At last, cell viability was estimated colorimetrically at 570 nm by an M200 plate reader (TECAN, Switzerland). The value of the absorbance in each group was normalized to that in the control group.
Colony formation assay
Briefly, 500 cells/well were seeded into a six-well plate. After full attachment, the cells were continuously cultured in the presence or absence of isogambogenic acid for 14 d. Clones were stained with 0.1% crystal violet for 15 min and photographed using the ChemiDocTM MP System (Bio-Rad, USA). Only those cell clusters containing more than 50 cells were counted.
Cell cycle analysis
Glioma cells were cultured with various concentrations of isogambogenic acid for 24 h and then suspended in 70% ethanol and fixed overnight at 4 °C. Cell cycle was detected using the Cell Cycle and Apoptosis Analysis Kit (Beyotime, P0010) according to the manufacturer's protocol with an Accuri C6 flow cytometer (BD Bioscience). The distribution of cells in G0/G1, S, and G2M phases was calculated using the ModFit LT software.
Transfection with adenovirus expressing the GFP-LC3B fusion protein
An adenovirus expressing the GFP-LC3B fusion protein (Ad-GFP-LC3B) was purchased from Beyotime, China. Cells grown to approximately 70% confluence were transfected with Ad-GFP-LC3B according to the manufacturer's instructions. Ad-GFP-LC3B-transduced glioma cells were treated with DMSO or different concentrations of isogambogenic acid, visualized by fluorescence microscopy and quantified with Image Lab software.
Western blot Glioma cells (3×10
5 cells/well) were seeded onto 6-cm dishes and treated according to the different experiments. Cells were harvested and then collected in RIPA lysis buffer (Thermo Scientific, USA) with protease and phosphatase cocktail inhibitors (Roche, 05892970001, 4906845001). The protein concentrations of each sample were quantified by BCA assay (Beyotime, P0010) according to the manufacturer's instructions. Total protein (20-100 μg) was separated by 6-15% SDS-PAGE gels and then transferred onto polyvinyl difluoride (PVDF) membranes (Millipore, IPVH00010) by the wet transfer method (Bio-Rad, USA). The membranes were blocked at room temperature for 1 h and were incubated with the indicated primary antibodies on an orbital shaker at 4 °C overnight. After washing with TBST, the HRP conjugated secondary antibody (ZSGBBIO, ZF-2301, ZF-2305) was applied for 1 hour at room temperature. Western blots were visualized using BeyoECL Star (Beyotime, P0018A) detection and quantified with Image Lab software.
Immunofluorescence Cells (5x10 4 ) were seeded onto 35-mm glass-bottomed dishes. Cells were treated according to the different experiments and fixed with 4% paraformaldehyde. Subsequently, cells were permeabilized using 0.1% Triton X-100 for 15 min and blocked with 10% bovine serum albumin (BSA; BOSTER, AR0004) for 1 h. Primary antibodies were diluted in 1% BSA and incubated at 4 °C overnight. After incubating for 1 h at 37 °C with AlexaFluor 488 AffiniPure goat anti-rabbit IgG (H+L) (ZSGBBIO, ZF-0155) in the dark, cells were incubated with DAPI (Beyotime, C1005) in a cassette for 5 min in the dark. Images were captured by the FSX100 Bio Imaging Navigator (Olympus, Japan). Data were standardized by Image-Pro Plus 6.0. Cell apoptosis detected by flow cytometry Cells apoptosis was detected by the Annexin V-FITC Apoptosis Detection Kit (BD Bioscience, 556547) according to the manufacturer's protocol. In brief, cells were plated in six-well plates and reached a level of 70-80% confluence. After treatment, cells were trypsin-released and Annexin-V/PI stained at room temperature for 20 min. Apoptotic cells were measured by Accuri C6 flow cytometer (BD Bioscience) and quantitated.
Transmission electron microscopy detection of the autophagosome Glioma cells (3×10 5 cells/well) were seeded onto 6-cm dishes for full attachment. After treatment, cells were harvested and fixed using 2.5% ice-cold glutaraldehyde at 4 °C overnight. Next, cells were dehydrated with ethanol and acetone. Next, cells were further fixed with 1% osmium tetroxide for 30 min. Then, cells were embedded in araldite and cut transversely in semithin sections (60 nm). The samples were contrasted with lead citrate-uranyl acetate and examined with a transmission electron microscope (Hitachi H-7650, Japan). 
Tumour xenograft model

Immunohistochemistry
Formalin-fixed, paraffin-embedded samples were sliced into 5 μm thick sections. Deparaffinized sections were incubated in H 2 O 2 for 10 min. In addition, the tumour sections were immunostained for primary antibodies (cleaved caspase-3, 1:200; Ki67, 1:100) at 4 °C overnight. Secondary antibody (ZSGB-BIO, PV6001) was applied for 30 min at 37 °C. The sections were developed with the Polink-2 plus® Polymer HRP Detection System (ZSGB-BIO, PV-9001) according to the manufacturer's protocol. Next, sections were visualized by using the diaminobenzidine (DAB) substrate kit (ZSGB-BIO, ZLI-9019) for 10 min. After intensive washing, sections were counterstained with haematoxylin, dehydrated and coverslipped. Then, the samples were observed with the FSX100 Bio Imaging Navigator (Olympus, Japan). Data were analysed with Image-Pro Plus 6.0.
Statistical analysis
Data are presented as the mean ± SD of three independent experiments. Comparisons between two groups were performed using a two-tailed Student's t-test. A single asterisk indicates statistical significance at P<0.05. Double asterisks indicate a strong statistical significance at P<0.01. Triple asterisks indicate even stronger statistical significance at P<0.001. All statistical analyses were completed using GraphPad Prism 5.0 software.
Results
Isogambogenic acid inhibits glioma cell growth
To examine the effect of isogambogenic acid on the viability of the human glioma cell lines U251 and U87, cell viability was determined using the MTT assay. As shown in Fig.  1B , in both cell lines, cell viability decreased in a dose-dependent manner when treated by isogambogenic acid. The IC50 of isogambogenic acid treatment for 24 h in glioma cells was 3-4 μM. Meanwhile, the immunofluorescent study showed that isogambogenic acid significantly decreased the expression of Ki67 in both cell lines (Fig. 1C) . Furthermore, the long-term Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry effects of isogambogenic acid on cell survival were determined by using a colony formation assay. The results showed that isogambogenic acid significantly suppressed the growth of glioma cells, as indicated by the decreased number of cell colonies in the isogambogenic acidtreated group (Fig. 1D ). In addition, the results showed that cells in G0/G1 phase increased and cells in the S phase decreased in a relatively dose-dependent manner (Fig. 1E ).
Isogambogenic acid induces autophagy in glioma cells
Increasing evidence has shown that autophagy plays an important role in anticancer therapies; therefore, we next investigated whether isogambogenic acid induces autophagy by examining autophagic vacuoles. With the transfection of Ad-GFP-LC3B, we first detected LC3B puncta formation. As shown, GFP-LC3B fluorescent puncta were increased in the U87 cells in a dose-dependent manner after cells were incubated with isogambogenic acid for 24 h ( Fig. 2A) . Furthermore, the conversion of LC3B-I to LC3B-II was also detected in a dose-dependent manner, suggesting that isogambogenic acid induced autophagic flux (Fig.  2B) . Moreover, transmission electron microscopy (TEM) analysis showed that autophagic vacuoles containing cellular material or membranous structures were increased in glioma cells treated with isogambogenic acid in a dose-dependent manner (Fig. 2C) . To further investigate whether isogambogenic acid could alter autophagic degradation, we monitored the levels of SQSTM1, which is associated with LC3 turnover and is lost during autolysosome degradation in a dose-dependent manner following isogambogenic acid incubation (Fig.  2D) . Together, these results demonstrated that isogambogenic acid induced autophagosome accumulation and promoted autophagic flux, indicating that isogambogenic acid was a potent autophagic flux inducer.
Inhibition of autophagy in the early or late stage has different effects on isogambogenic acid-induced autophagy
Next, the autophagy inhibitors 3-MA and CQ were used to investigate the role of isogambogenic acid in glioma cells. 3-MA and CQ block the upstream and downstream steps of autophagy [8] . The results indicated that 3-MA (1 mM) attenuated isogambogenic acidinduced cell death, while CQ (5 μM) significantly enhanced the isogambogenic acid-induced cytotoxicity (Fig. 3A, B) . Then, we detected the autophagy level using TEM and western blot. The data indicated that 3-MA blocked isogambogenic acid-induced autophagy, which was shown by a reduced level of LC3-II and reduced number of autophagic vacuoles (Fig.  3C, D) . Unlike 3-MA, CQ treatment led to an isogambogenic acid-induced increase in the [10, 19] . Additionally, AMPK has been demonstrated as an inhibitor of the activation of mTOR [20] . Data have shown that mTOR plays an important role in the autophagy of glioma cells [12, 21] . We then examined whether isogambogenic acid had an effect on autophagy via the AMPKmTOR pathway. In this study, we observed that isogambogenic acid induced AMPKα phosphorylation at Thr172 and decreased mTOR phosphorylation at Ser-2448 in a dose-dependent manner in U87 cells. It is well known that mTOR regulates autophagy through the activation of 4E-BP1 [12] . Our results demonstrated that isogambogenic acid also inhibited 4E-BP1 phosphorylation at Thr43/46 in glioma cells (Fig.  4A) . To further investigate the role of isogambogenic acidinduced AMPK activation in mTOR inhibition, the AMPK activator metformin hydrochloride (Met) and the mTOR inhibitor rapamycin were utilized. The results indicated that pretreatment with Met (2 mM) obviously induced AMPK phosphorylation and inhibited mTOR and 4E-BP1 phosphorylation.
Additionally, our data indicated that co-treatment with Met induced a stronger activation of AMPK and inhibition of mTOR and 4E-BP1 than isogambogenic acid or Met treatment alone in U87 cells (Fig. 4B) . Rapamycin (30 nM) obviously inhibited AMPK, mTOR and 4E-BP1 phosphorylation. Our data further indicated that co-treatment with rapamycin induced more AMPK, mTOR and 4E-BP1 inhibition than treatment with isogambogenic acid or rapamycin alone (Fig.  4C) . Additionally, our data indicated that co-treatment with isogambogenic acid and Met led to a stronger LC3 conversion and induction of cell death than isogambogenic acid or Met treatment alone (Fig. 5A, B) . Furthermore, isogambogenic acid combined with rapamycin induced more LC3 conversion and cytotoxicity than treatment with isogambogenic acid or rapamycin alone (Fig. 5C, D) . Therefore, isogambogenic acid appears to be both an AMPK Fig. 4 . AMPK-mTOR signalling is involved in isogambogenic acid-induced autophagy. (A) U87 cells were treated with isogambogenic acid for 24 h. Expression levels of the phosphorylation of AMPK, mTOR and 4E-BP1 were assessed by western blotting, and total AMPK, mTOR and 4E-BP1 were used as the internal controls, respectively. (B) U87 cells were treated with Met alone or in the presence of isogambogenic acid for 24 h. The expression levels of phosphorylated AMPK, mTOR and 4E-BP1 were assessed by western blotting, with total AMPK, mTOR and 4E-BP1 used as the internal controls. (C) U87 cells were treated with rapamycin alone or in the presence of isogambogenic acid. Expression levels of phosphorylated AMPK, mTOR and 4E-BP1 were assessed by western blotting, with total AMPK, mTOR and 4E-BP1 used as the internal controls. * P<0.05, ** P<0.01, *** P<0.001 when compared with control. All data are representative of 3 independent experiments. 
Apoptosis occurs in isogambogenic acid-treated glioma cells
To further evaluate whether isogambogenic acid-induced cell death was associated with apoptosis, the morphological changes of isogambogenic acid-treated glioma cells were examined by Hoechst staining and TEM. Apoptotic cell membrane shrinkage, nuclear membrane shrinkage, chromatin condensation and apoptotic bodies were observed in glioma cells treated with isogambogenic acid for 24 h (Fig. 6A) . Further, we evaluated cleaved caspase-3 protein expression levels and the percentage of apoptotic cells. Isogambogenic acid increased the expression of apoptosis-related cleaved caspase-3 protein and the percentage of Annexin V-positive cells (Fig. 6B) . Next, we investigated the relationship between autophagy and apoptosis in isogambogenic acid-treated glioma cells. The results indicated that 3-MA (1 mM) blocked isogambogenic acid-induced (10 µM) apoptosis, which was shown by a reduced level of expression of the apoptosis-related cleaved caspase-3 protein and a lower percentage of Annexin V-positive cells (Fig. 6C) . Moreover, we examined whether the AMPK-mTOR pathway had an effect on apoptosis in the isogambogenic acid-treated glioma cells. Our data further indicated that co-treatment with Met (2 mM) induced a higher level of apoptosis than isogambogenic acid (10 µM) or Met treatment alone in U87 cells (Fig. 6D) . In all, apoptosis occurs in isogambogenic acid-treated glioma cells, and activation of the AMPKmTOR pathway enhanced apoptosis in isogambogenic acid-treated glioma cells.
Isogambogenic acid suppresses glioma growth and induces autophagy in vivo
Next, we investigated the effect of isogambogenic acid on glioma growth in vivo. Data showed that isogambogenic acid reduced the volume and weight of glioma tumours in a (Fig. 7A, B) . Next, we examined the relationship between isogambogenic acid and autophagy in glioma.
As shown in Fig. 7C , the protein expressions of LC3-II/LC3-I in the tumours of the isogambogenic acid group were higher than in the salinetreated group. In addition, elevated phosphorylation levels of AMPK and cleavedcaspase-3 and a decreased expression of Ki67 were observed in the isogambogenic acid-treated group compared with the controls in vivo (Fig.  7D, E) . All together, these data supported isogambogenic acidmediated growth suppression of glioma related to the AMPKmTOR pathway and autophagic and apoptotic cell death in vivo.
Discussion
In recent years, many studies have focused on identifying anti-glioma agents that can suppress tumour growth with fewer side effects [22] [23] [24] . It has been well established that autophagy is closely implicated in the occurrence and development of glioma [10, 25] . Intervening in autophagy has been accepted as one of the effective measures for glioma treatment [26, 27] . Our results, as shown in Fig. 8 , suggested for the first time that isogambogenic acid induced autophagy and apoptosis and decreased the expression of Ki67 and colony formation in vitro and in vivo. Isogambogenic acid will be a potent anti-glioma agent after further research.
In this study, we investigated that isogambogenic acid suppressed cell growth and the expression level of Ki67, an important proliferative marker. According to relevant research reports, isogambogenic acid has low toxicity to zebrafish embryos [28] . In addition, recent studies show that cell cycle regulation is an attractive target in cancer therapy, especially in Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry gliomas [29, 30] . Cell cycle arrest triggers tumour senescence and prevents tumour progression and have not any obvious effects on normal tissues, which may be related to the inhibition of regulators such as CDK1, D-type cyclins, CDK4 and CDK6 [31, 32] . Our data showed that isogambogenic acid led to cell cycle arrest in human glioma U87 and U251 cells, so this drug has a good toxicity against gliomas and may have a low toxicity in normal tissues. In addition, isogambogenic acid can disrupt autophagy and stimulate apoptosis and the mechanisms of drug action is associated with AMPK and mTOR related pathways. The activation of these pathways in normal cells is markedly different from that of tumours, so it can be inferred that isogambogenic acid may have little effect on normal cells [13, 33] . Further experiments on the increased conversion of LC3-I to LC3-II, SQSTM1 clearance and massive autophagic vacuoles in isogambogenic acid-treated glioma cells suggested that autophagy was activated by isogambogenic acid. In addition, another finding indicated that isogambogenic acid-related autophagy can be strengthened by inhibiting the late stage of autophagy. Increased conversion of LC3-I to LC3-II and massive autophagic vacuoles induced by isogambogenic acid can be attenuated by 3-MA but strengthened by CQ. This suggested that 3-MA inhibited autophagy flux initiation and attenuated isogambogenic acid-related autophagy. CQ inhibited autophagosome-lysosome fusion and the degradation steps induced by isogambogenic acid, enhancing autophagic vacuole accumulation and the cytotoxic effects of isogambogenic acid on glioma cells.
Furthermore, our data indicated that the effects of isogambogenic acid on glioma cells are associated with the AMPK-mTOR signalling pathway. As is well recognized, the key role of mTOR is as a repressor of autophagy; the decrease in mTOR activity can effectively initiate the autophagic response in glioma cells [34] [35] [36] . Activation of AMPK leads to the inhibition of mTOR, which also propels autophagy [33] . In line with our study, previous evidence has shown that activation of the AMPK-mTOR pathway induces autophagy in glioma cells [37] . In this report, we found that isogambogenic acid-induced autophagy was associated with the AMPK-mTOR pathway and that isogambogenic acid attenuated mTOR signalling via activation of the AMPK-dependent pathway. Moreover, activation of the AMPK-mTOR pathway enhanced isogambogenic acid-induced autophagy and inhibited the growth of 
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Cellular Physiology and Biochemistry glioma cells, which further indicates that isogambogenic acid inhibits induced autophagy and the growth of glioma cells through activation of the AMPK-mTOR pathway.
As we know, programmed cell death can be divided into apoptotic and autophagic cell death. Until now, studies have shown three different effects of autophagy on apoptosis to induce cell death: antagonizing apoptosis, facilitating apoptosis or cooperating with apoptosis [38] . In normal cells, the onset of moderate autophagy usually inhibits the occurrence of apoptosis [39] . However, excessive autophagy in cells stimulated by drugs and other factors may play an important role in apoptosis [40, 41] . In the present study, we found that both apoptosis and autophagy were induced after isogambogenic acid treatment. Fig. 8 depicts the hypothesized mechanism of isogambogenic acid-induced autophagy and apoptosis in gliomas. Inhibition of autophagy by 3-MA led to a decreased apoptosis level, indicating that autophagy may act as an apoptosis promoter to induce glioma cell death after isogambogenic acid treatment and that inhibition of the early steps of autophagy reduced caspase-dependent cell death [42] . Autophagy contributes to apoptosis by several different means, such as enabling membrane blebbing and phosphatidylserine exposure by maintaining ATP levels [43] . Similar to our results, studies by Young et al. found that autophagosome formation has been implicated in the process of apoptosis. Moreover, they found that inhibition of the early stage of autophagy reduced the activation of caspase-8 and caspase-3, while the effect of late autophagy inhibition was the opposite [42] . In addition to autophagy, several studies have shown that the activation of AMPK and inhibition of mTOR is closely related to apoptosis [44] [45] [46] [47] . In our study, activation of the AMPK-mTOR pathway led to a higher amount of apoptosis, which suggests that the AMPK-mTOR pathway may also contribute to isogambogenic acid-induced apoptosis in glioma cells. Nevertheless, the antineoplastic mechanisms of isogambogenic acid are complex. The relationship between the autophagy and apoptosis induced by isogambogenic acid and the underlying mechanisms are worthy of further exploration.
Conclusion
Our work shows that isogambogenic acid, a natural autophagic inducer, induces autophagy and apoptosis by regulating the AMPK-mTOR pathway in glioma cells. In addition, targeting autophagy, apoptosis and related signalling pathways may provide new strategies for glioma treatment.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
